CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) hit a new 52-week low on Monday. The stock traded as low as $1.95 and last traded at $1.98, with a volume of 12,907,562 shares. The stock had previously closed at $2.19.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on CTMX. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a report on Friday, September 11th. JPMorgan Chase & Co. reduced their target price on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating on the stock in a research note on Thursday, August 13th. Guggenheim reduced their target price on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Wedbush lifted their target price on CytomX Therapeutics from $11.00 to $12.00 and gave the stock an “outperform” rating in a research report on Friday, November 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of CytomX Therapeutics in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CytomX Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.
Check Out Our Latest Research Report on CTMX
CytomX Therapeutics Stock Up 7.6%
The stock’s 50 day moving average price is $2.66 and its 200-day moving average price is $3.78. The stock has a market capitalization of $464.12 million, a P/E ratio of -4.26 and a beta of 2.23.
CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). CytomX Therapeutics had a negative return on equity of 33.97% and a negative net margin of 608.98%. The company had revenue of $1.69 million for the quarter, compared to analysts’ expectations of $10.38 million. Analysts anticipate that CytomX Therapeutics, Inc. will post -0.40 earnings per share for the current year.
Institutional Investors Weigh In On CytomX Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC raised its holdings in CytomX Therapeutics by 154.1% in the third quarter. Private Advisor Group LLC now owns 138,468 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 83,966 shares in the last quarter. IFG Advisory LLC bought a new stake in shares of CytomX Therapeutics in the 3rd quarter valued at about $569,000. Almanack Investment Partners LLC. bought a new stake in shares of CytomX Therapeutics in the 3rd quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of CytomX Therapeutics in the 3rd quarter valued at about $30,000. Finally, Peak Financial Advisors LLC purchased a new position in shares of CytomX Therapeutics in the 3rd quarter worth approximately $1,257,000. Institutional investors own 67.77% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Founded in 2008 and headquartered in South San Francisco, California, the company researches therapies designed to target tumors while limiting activity in healthy tissues. Its Probody platform uses molecular masks intended to keep therapeutic antibodies inactive until they encounter enzymes associated with the tumor environment. CytomX applies this approach to investigational medicines, including antibody-drug conjugates and immune-cell-engaging therapies.
Featured Stories
- Five stocks we like better than CytomX Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
